News Sobi stays on its acquisitive streak with $915m Dova deal Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
